Roche targets 100 Spanish jobs in restructuring; U.S. court reinstates Botox marketing claims;

@FiercePharma: Tops in FiercePharmaManufacturing Tues: Boehringer Ingelheim recalls cancer drug made at ill-fated Bedford plant. Article | Follow @FiercePharma

@EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury cars, arrest a dozen. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Teva trounces patent on AstraZeneca's Symbicort, opening up U.K. copycat launch. Story | Follow @CarlyHFierce

> Roche ($RHHBY) will ax 100 jobs in Spain in a restructuring of its operations in the country, citing price controls as one motivating factor. Report

> Allergan ($AGN) has to face a shareholder lawsuit over allegedly improper Botox marketing, the Ninth Circuit Court of Appeals ruled, overturning a lower court's dismissal of the claims. Report

> Merck KGaA broke ground on another addition to its revamped Darmstadt, Germany, headquarters. Release

> U.K. cost-effectiveness watchdogs called for the country's Cancer Drugs Fund to adopt its framework for evaluating treatments. Report

> Armed with new data on brain shrinkage in multiple sclerosis patients, Novartis ($NVS) is calling for a new version of treatment goals. Report

> Iroko Pharmaceuticals said its new arthritis pain reliever Zorvolex won spots on key managed care formularies. Release

Medical Device News

@FierceMedDev: ICYMI: ArthroCare $750M fraud saga culminates in decades-long prison term. Article | Follow @FierceMedDev

@VarunSaxena2: Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? FierceDrugDelivery story | Follow @VarunSaxena2

@MichaelGFierce: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Bionic eye bridges gap between visual signals and brain, gives blind patients a chance to see. More from The Atlantic | Follow @EmilyWFierce

> FDA clears wireless, vitals monitor patch that transmits to smartphone. Story

> J&J shoring up for latest courtroom battle over all-metal hip implant. Article

Biotech News

@FierceBiotech: $RHHBY CEO Schwan took a hands-on approach negotiating $8.3B $ITMN buyout. Report | Follow @FierceBiotech

@JohnCFierce: $GSK's new Boston collaboration chief goes 'anti-pharma' as he prowls for partners. Story | Follow @JohnCFierce

@DamianFierce: Steven Paul (former $LLY exec, $SAGE co-founder) takes the helm at Third Rock's Voyager Therapeutics. Release (PDF) | Follow @DamianFierce

@EmilyMFierce: Ebola treatments caught in limbo. More from Nature | Follow @EmilyMFierce

> Teva's well-traveled asthma drug comes through in Phase III. News

> Feds pledge up to $42M to hit the gas on Mapp's Ebola drug. More

> AbbVie ties the knot with Infinity in $805M blood cancer collaboration. Report

Drug Delivery News

> UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. More

> RNAi pipeline active as investors, patients wait for commercialization. Item

> BioTime enters academic collaborations to advance its hydrogel for vocal fold scarring. Article

> Artificial virus promises effective drug delivery and gene therapy. Story

> Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? Report

Diagnostics News

> Companion diagnostics crossed the billion-dollar threshold in 2013: Report. More

> Finnish gene sequencing Dx startup wins funding to back U.S. expansion. Report

> Quest scientists and others identify new rheumatoid arthritis biomarker. Item

> NanoString mourns the sudden death of its CMO. Story

> MIT discovers malaria parasitic waste has Dx biomarker potential. Article

Pharma Marketing News

> J&J, Bayer look to turbocharge Xarelto with new label-expanding studies. More

> Genzyme puts $310,250 price tag on new Gaucher-fighting pill. Article

> Actavis' Namenda switch exceeds expectations, and its ability to supply new version. Item

> GSK can't deep-clean its image overnight. But it can revamp its websites. Story

> Novartis sees 'most exciting launch' ever with megablockbuster-to-be heart drug. Report

And Finally... Should companies reimburse executives for special inversion-deal taxes? Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.